These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1493390)

  • 1. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective.
    Gustafsson C; Asplund K; Britton M; Norrving B; Olsson B; Marké LA
    BMJ; 1992 Dec; 305(6867):1457-60. PubMed ID: 1493390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation.
    Gage BF; Cardinalli AB; Albers GW; Owens DK
    JAMA; 1995 Dec; 274(23):1839-45. PubMed ID: 7500532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
    Lancet; 1993 Nov; 342(8882):1255-62. PubMed ID: 7901582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
    Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapy in atrial fibrillation.
    Turpie AG; Connolly SJ
    Can Fam Physician; 1996 Jul; 42():1341-5. PubMed ID: 8754703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost savings of newer oral anticoagulants in atrial fibrillation-related stroke prevention
.
    Masbah N; Macleod MJ
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):220-230. PubMed ID: 28025962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation.
    Saw J; Bennell MC; Singh SM; Wijeysundera HC
    Can J Cardiol; 2016 Nov; 32(11):1355.e9-1355.e14. PubMed ID: 27432692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.
    Kumar S; de Lusignan S; McGovern A; Correa A; Hriskova M; Gatenby P; Jones S; Goldsmith D; Camm AJ
    BMJ; 2018 Feb; 360():k342. PubMed ID: 29444881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.
    Reddy VY; Akehurst RL; Armstrong SO; Amorosi SL; Brereton N; Hertz DS; Holmes DR
    Europace; 2016 Jul; 18(7):979-86. PubMed ID: 26838691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study.
    Lancet; 1994 Mar; 343(8899):687-91. PubMed ID: 7907677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective.
    Ademi Z; Pasupathi K; Liew D
    Appl Health Econ Health Policy; 2017 Jun; 15(3):363-374. PubMed ID: 27699648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.